Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Breast cancer is a collective term used to describe various subtypes of breast tumors that originate from distinct molecular and cellular sources, each exhibiting unique clinical characteristics. The majority of these tumors are epithelial in nature and arise from either the ductal or lobular tissue. Early-stage breast cancers often lack noticeable symptoms, and patients typically do not experience pain or discomfort. However, the presence of a lump may indicate the potential presence of breast cancer. Additional indicators of breast cancer may include changes in breast size or shape, skin dimpling or alterations, recent nipple inversion or abnormalities, discharge from a single duct, particularly if it is blood-stained, and the presence of an axillary lump. There are seven broad categories of risk factors associated with breast cancer. These factors include age, gender, personal history of breast cancer, histologic risk factors, family history of breast cancer and genetic risk factors, reproductive risk factors, and exogenous hormone use. Breast cancer development occurs as a result of DNA damage and genetic mutations, which can be influenced by exposure to estrogen. In some cases, there may be an inherited presence of DNA defects or pro-cancerous genes such as BRCA1 and BRCA2. Breast cancer is classified using the TNM classification system, which categorizes patients into four stage groups based on the size of the primary tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The classification system most commonly used is that of the American Joint Committee on Cancer. Differential diagnoses may include breast abscess, fat necrosis, and fibroadenoma. The prognosis for early-stage breast cancer is generally favorable. Stage 0 and stage I breast cancers exhibit a 100% 5-year survival rate. Stage II and stage III breast cancers have approximate 5-year survival rates of 93% and 72%, respectively. However, when the disease metastasizes to other parts of the body, the prognosis significantly worsens. Only 22% of stage IV breast cancer patients survive beyond the next 5 years.

  • The age-adjusted incidence of female breast cancer is estimated to be 129.2 per 100,000 women.

Thelansis’s “Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more